FEATURED ARTICLES
MORE FROM THIS ISSUE
InforMS: Winter 2022
Hot Topics in MS: What’s New? What’s Next? What Do People Want to Know?
By Rocky Mountain MS Center
In this issue, we’ve compiled six reports on “hot topics” in the MS world. These topics are based on both input from the Rocky Mountain MS Center medical team, and...
InforMS: Winter 2022
Hot Topics in MS: COVID-19 — Is It Over?
By Peter Broderick
Not Exactly... But Vaccines and Boosters Remain Our Best Defense COVID-19 continues to twist and turn as new variants become more predominant. The BQ1 and BQ1.1 variants have become the...
InforMS: Winter 2022
Hot Topics in MS: Epstein Barr Virus and MS
By Kerri Cechovic
Over the past several months, there has been increased interest in the relationship between the Epstein Barr Virus and multiple sclerosis. A study conducted by a Harvard University research team...
InforMS: Winter 2022
Hot Topics in MS: Remyelination — Can MS Damage be Repaired?
By Peter Broderick
Repair of MS damage and the potential for the reversal of the effects of MS are always on the minds of doctors, researchers and those living with the disease. Despite...
InforMS: Winter 2022
Hot Topics in MS: Stem Cell Treatment in MS
By Kelsey Morrow
With current disease modifying therapies (DMTs) we have several highly effective treatments that work for many people, but there is a percentage of the population for whom these medications do...
InforMS: Winter 2022
Hot Topics in MS: Biomarkers
By Peter Broderick
A biomarker is any measurable indicator that can reliably and accurately tell us about a biological state or medical condition. As we continue to learn more about MS and utilize...
InforMS: Winter 2022
Hot Topics in MS: Tyrosine Kinases Inhibitors Studied for Treatment of MS
By Kerri Cechovic
A whole new family of drugs is currently being studied very aggressively for the treatment of MS: Tyrosine kinases Inhibitors. Tyrosine kinases (TYKs) are intracellular enzymes that play a key...
InforMS: Winter 2022
Rocky Mountain MS Center at University of Colorado Biobank
By Rocky Mountain MS Center
Biomarkers are biological markers that can be used in diagnosis, selecting treatments, and evaluating treatment responses. Having pre-collected samples is invaluable for this research, and the Biobank ensures that researchers...
InforMS: Winter 2022
Current Biomarker Studies Underway at the Rocky Mountain MS Center at University of Colorado
By Rocky Mountain MS Center
NfL and GFAP as Measures of Disease Progression Prospective study to evaluate Neurofilament Light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for disease progression over time in patients...
You're Reading:
About the Author
This content was compiled by Rocky Mountain MS Center staff members.